Drug Uses

Lamisil Tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes.

How Taken

Lamisil comes as a tablet to take orally. It is usually taken once a day for 6 weeks for fingernail fungus and once a day for 12 weeks for toenail fungus. Take Lamisil exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Your fungus may not be completely cured until a few months after you finish taking Lamisil. This is because it takes time for a healthy nail to grow in.

Warnings/Precautions

Do not take Lamisil without first talking to your doctor if you have ever had an allergic reaction to it, liver disease, kidney disease, problems with your immune system, or blood problems. You may not be able to take Lamisil, or you may require a dosage adjustment or special monitoring if you have any of the conditions listed above. Lamisil is in the FDA pregnancy category B. This means that it is not expected to harm an unborn baby. Do not take Lamisil without first talking to your doctor if you are pregnant. Lamisil passes into breast milk and may affect a nursing baby. Do not take this medication without first talking to your doctor if you are breast-feeding a baby.

Missed Dose

Take the missed dose as soon as you remember. However, if it is almost time for the next regularly scheduled dose, skip the missed dose and take the next one as directed. Do not take a double dose of this medication.

Possible Side Effects

If you experience any of the following serious side effects, stop taking Lamisil and seek emergency medical attention: an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives); a rash; changes in vision; or blood problems (detected by blood tests). In rare cases, Lamisil has caused severe liver damage, sometimes resulting in liver transplant or death. Notify your doctor immediately if you develop nausea, vomiting, abdominal pain, unusual fatigue, loss of appetite, yellow skin or eyes, itching, dark urine, or clay colored stools. These symptoms may be early signs of liver damage. Other, less serious side effects may be more likely to occur. Continue to take Lamisil and talk to your doctor if you experience nausea, upset stomach, or heartburn; diarrhea or flatulence; headache; or taste disturbances or a loss of taste. Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

Storage

Store tablets below 25o C (77o F); in a tight container. Protect from light.

Overdose

Clinical experience regarding overdose with Lamisil Tablets is limited. The symptoms of overdose included nausea, vomiting, abdominal pain, dizziness, rash, frequent urination, and headache. Seek emergency medical attention.

More Information

Avoid alcohol or use it in moderation while taking Lamisil. Alcohol and Lamisil can both affect the liver. Lamisil Tablets are contraindicated if you have a hypersensitivity to Lamisil.

Disclaimer

This drug information is for your information purposes only, it is not intended that this information covers all uses, directions, drug interactions, precautions, or adverse effects of your medication. This is only general information, and should not be relied on for any purpose. It should not be construed as containing specific instructions for any particular patient. We disclaim all responsibility for the accuracy and reliability of this information, and/or any consequences arising from the use of this information, including damage or adverse consequences to persons or property, however such damages or consequences arise. No warranty, either expressed or implied, is made in regards to this information.

Other info about Lamisil-oral at Wikipedia.org and other resources:

A novel method for fast and robust estimation of fluorescence decay dynamics using constrained least-squares deconvolution with Laguerre expansion.
We report a novel method for estimating fluorescence impulse response function (fIRF) from noise-corrupted time-domain fluorescence measurements of biological tissue. This method is based on the use of high-order Laguerre basis functions and a constrained least-squares approach that addresses the problem of overfitting due to increased model complexity. The new method was extensively evaluated on fluorescence data from simulation, fluorescent standard dyes, ex vivo tissue samples of atherosclerotic plaques and in vivo oral carcinoma. Current results demonstrate that this method allows for rapid and accurate deconvolution of multiple channel fluorescence decays without adaptively adjusting the Laguerre scale parameter. The appropriate choice of the scale parameter is essential for accurate ...

Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants.
We examined the frequency of the most relevant variants encoding CYP2C9 (alleles *1, *2 and *3) and VKORC1 (SNP -1639A>G) in the Argentinian population. Molecular typing was performed by PCR-RFLP on a randomly selected sample of 101 healthy volunteers from the Hospital Italiano de Buenos Aires gene bank. Fifty-seven subjects were identified as homozygous for CYP2C9*1 and 14 for *2, while 24 and 5 were heterozygous for *2 and *3 alleles; one individual was a composite heterozygote (*2/*3). When we examined VKORC1, 21 subjects were AA homozygous, 60 were AG heterozygotes and 20 were GG homozygotes. This is the first analysis of genotypic frequencies for CYP2C9 and VKORC1 performed in an Argentinian population. These allele prevalences are similar to what is known for Caucasian population,...

Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study
Mandhaniya S, Swaroop C, Thulkar S, Vishnubhatla S, Kabra SK, Xess I, Bakhshi S (Source: The Aspergillus Website - articles)

Fingolimod: new oral treatment for relapsing‐remitting MS
AbstractFingolimod (Gilenya) is an oral disease‐modifying therapy licensed for relapsingremitting multiple sclerosis (RRMS) in patients with high disease activity despite treatment with an interferon beta. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events, and Drs Klaus Schmierer and Rachel Farrell discuss its place in place in the treatment of RRMS. Copyright © 2012 Wiley Interface Ltd (Source: Prescriber)

Management of resistant Gram‐negative urinary tract infections
AbstractThe authors discuss current oral and intravenous treatment options in the management of multiresistant Gram‐negative urinary tract infections in the community. Copyright © 2012 Wiley Interface Ltd (Source: Prescriber)